For example, when treated with CHOP‐like and augmented CHOP‐like therapies, the 5‐year survival in MYC+ DLBCL patients was inferior compared to MYC− patients (44% vs. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.